Similarly in patients with NSCLC, among other cancers, receiving anti-PD-1 immunotherapy, lncRNA RP11-705C-15.3 levels have been considered a putative prognostic factor for the treatment outcome [137]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.